How has Lilly defended its insulin record?

Lilly argues that the healthcare system, not manufacturer greed, created affordability problems, and that it has moved faster than rivals to fix them. Announcing its 2023 price cuts, CEO David Ricks said the system still does not provide affordable insulin for everyone and "that needs to change". He called on others to "meet us at this point" and said the cuts had been planned for some time.

Lilly also launched Rezvoglar, an interchangeable biosimilar to Sanofi's Lantus, at $92 per five-pack, a 78% discount, and said its unbranded lispro at $25 a vial was cheaper than a Humalog vial in 1999. Lilly's $35 cap applies at around 85% of US pharmacies, with rebates for patients elsewhere. Critics respond that the cuts followed years of increases and coincided with political and legal pressure.